Research presented at ENDO 2024 shows that nearly 2 years after receiving a full course of the IGF-IR inhibitor teprotumumab, 82% of patients with thyroid eye disease did not need further treatment for symptoms like proptosis and diplopia. The study, led by Dr. George Kahaly, analyzed data from the phase 2/3 OPTIC and OPTIC-X studies, with results showing sustained improvements in symptoms even 51 weeks after therapy. Most participants maintained response to teprotumumab, with minimal adverse effects reported. These findings provide longer-term data supporting the use of teprotumumab in appropriate patients with thyroid eye disease. The study was sponsored by Amgen.
Source link
Teprotumumab Gives Lasting Relief from Thyroid Eye Disease
